Literature DB >> 17544968

Epidemiology and natural history of NAFLD and NASH.

Janus P Ong1, Zobair M Younossi.   

Abstract

Understanding of the epidemiology and natural history of non-alcoholic fatty liver disease (NAFLD) has increased; it is the most common form of chronic liver disease in the Western world and increasing in importance in other parts of the world. Prevalence is expected to increase as obesity and diabetes epidemics evolve. The natural history of NAFLD depends on the histologic subtype. Those who have simple hepatic steatosis or nonspecific inflammation generally have a benign long-term prognosis, whereas non-alcoholic steatohepatitis (NASH) can progress to cirrhosis. NASH-related cirrhosis may have a similar prognosis as cirrhosis from other causes, leading to liver failure or hepatocellular carcinoma.

Entities:  

Mesh:

Year:  2007        PMID: 17544968     DOI: 10.1016/j.cld.2007.02.009

Source DB:  PubMed          Journal:  Clin Liver Dis        ISSN: 1089-3261            Impact factor:   6.126


  133 in total

1.  Hepatic lipogranulomas in patients with chronic liver disease: association with hepatitis C and fatty liver disease.

Authors:  Hongfa Zhu; Henry C Bodenheimer; David J Clain; Albert D Min; Neil D Theise
Journal:  World J Gastroenterol       Date:  2010-10-28       Impact factor: 5.742

2.  Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

Authors:  S E Inzucchi; R M Bergenstal; J B Buse; M Diamant; E Ferrannini; M Nauck; A L Peters; A Tsapas; R Wender; D R Matthews
Journal:  Diabetologia       Date:  2012-04-20       Impact factor: 10.122

3.  Challenging the rodent hegemony: a new rabbit model of nonalcoholic steatohepatitis.

Authors:  Jaideep Behari; Naga Chalasani
Journal:  Am J Pathol       Date:  2010-05-20       Impact factor: 4.307

4.  Hepatic gene expression of Caucasian and African-American patients with obesity-related non-alcoholic fatty liver disease.

Authors:  Maria Stepanova; Noreen Hossain; Arian Afendy; Kellie Perry; Zachary D Goodman; Ancha Baranova; Zobair Younossi
Journal:  Obes Surg       Date:  2010-01-30       Impact factor: 4.129

5.  Portal lymphadenopathy predicts non-alcoholic steatohepatitis and advanced fibrosis in non-alcoholic fatty liver disease.

Authors:  Saleh Daher; Namma Lev Cohen; Muhammad Massarwa; Mahmud Mahamid; Mira Nasser; Wadi Hazou; Rani Oren; Rifaat Safadi; Tawfik Khoury
Journal:  PLoS One       Date:  2018-11-30       Impact factor: 3.240

6.  Treatment options for nonalcoholic fatty liver disease.

Authors:  Brian Lam; Zobair M Younossi
Journal:  Therap Adv Gastroenterol       Date:  2010-03       Impact factor: 4.409

Review 7.  Nonalcoholic fatty liver disease.

Authors:  Sandra K Erickson
Journal:  J Lipid Res       Date:  2008-12-12       Impact factor: 5.922

8.  Proton density fat-fraction is an accurate biomarker of hepatic steatosis in adolescent girls and young women.

Authors:  Jennifer L Rehm; Peter M Wolfgram; Diego Hernando; Jens C Eickhoff; David B Allen; Scott B Reeder
Journal:  Eur Radiol       Date:  2015-04-28       Impact factor: 5.315

Review 9.  Fatty liver: a link to cardiovascular disease--its natural history, pathogenesis, and treatment.

Authors:  Howard P Monsour; Catherine T Frenette; Kathleen Wyne
Journal:  Methodist Debakey Cardiovasc J       Date:  2012 Jul-Sep

10.  NAFLD prevalence differs among hispanic subgroups: the Multi-Ethnic Study of Atherosclerosis.

Authors:  Michael Wayne Fleischman; Matthew Budoff; Ifran Zeb; Dong Li; Temitope Foster
Journal:  World J Gastroenterol       Date:  2014-05-07       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.